The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
 
Richard D. Kim
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Lilly
Speakers' Bureau - Lilly; Taiho Pharmaceutical
Research Funding - Bayer; Eisai; Novartis
 
Andrew Stewart Poklepovic
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - Pfizer
Research Funding - Acceleron Pharma; Amgen; Genentech/Roche; Incyte; Leadiant Biosciences; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma
 
Dae Won Kim
No Relationships to Disclose
 
Heloisa P. Soares
Consulting or Advisory Role - Cornerstone Pharmaceuticals; Ipsen
Speakers' Bureau - Celgene; Novartis
 
Jongphil Kim
No Relationships to Disclose
 
Jun Min Zhou
No Relationships to Disclose
 
Fatima Tariq
No Relationships to Disclose
 
Natalie Burgess
No Relationships to Disclose
 
Hanna Kelly Sanoff
Research Funding - Bayer (Inst); Merck (Inst)